Document is current
Any future updates will be listed below
-
Authors
Sheng, Iris Y.
Diaz-Montero, Claudia Marcela
Rayman, Patricia
Wei, Wei
Finke, James H.
Kim, Jin S.
Pavicic, Paul G. Jr.
Lamenza, Marcelo
Company, Donna
Stephenson, Andrew
Campbell, Steven
Haber, George
Lee, Byron
Mian, Omar
Gilligan, Timothy D.
Rini, Brian I.
Garcia, Jorge A.
Grivas, Petros
Ornstein, Moshe C.
- License Information
-
More Information
Article History
First Online: 23 March 2020
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this article.
: Brian I. Rini declares research funding and consulting for Merck, BMS, Pfizer, Roche, Aveo. Jorge A. Garcia declares consulting for Merck, Janssen, Eisai, Astella, Seattle Genetics and speaking/education for Merck, Janssen and Bayer. Petros Grivas declares prior unrelated consulting for: AstraZeneca; Bayer; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; Heron Therapeutics; Janssen; Merck & Co.; Mirati Therapeutics; Pfizer; Seattle Genetics; QED Therapeutics; Roche; research funding to institution: AstraZeneca, Bayer; Genentech/Roche; Merck & Co.; Mirati Therapeutics; Oncogenex; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb. Moshe C. Ornstein declares grant support from Pfizer, BMS; speaking: BMS, Exelixis; education support: Pfizer; consulting: BMS, Pfizer, Exelixis. Iris Y. Sheng, Claudia Marcela Diaz-Montero, Patricia Rayman, Wei Wei, James H. Finke, Jin S. Kim, Paul G Pavicic Jr, Marcelo Lamenza, Donna Company, Andrew Stephenson, Steven Campbell, George Haber, Byron Lee, Omar Mian, and Timothy D. Gilligan declare that they have no conflicts of interest that might be relevant to the contents of this article.
